EBMT Exclusive Interview | Professor Yanmin Zhao: Maintenance Treatment Strategies for FLT3-ITD Mutant AML Patients After Transplantation
FMS-like tyrosine kinase 3 (FLT3) mutations, particularly internal tandem duplication mutations (FLT3-ITD), are one of the significant factors affecting the prognosis of patients with acute myeloid leukemia (AML). Overcoming the challenge of relapse after transplantation in patients with FLT3-mutated AML remains a significant clinical hurdle. At the 50th European Bone Marrow Transplantation (EBMT) annual meeting, Professor Yanmin Zhao from The First Affiliated Hospital of Zhejiang University School of Medicine presented a study (Abstract No.: OS18-08), which explored the impact of mutations in myelodysplasia-related (MR) genes on maintenance treatment outcomes after transplantation for FLT3-ITD AML patients. "Oncology Frontier - Hematology Frontier" invited Professor Yanmin Zhao to share insights into the maintenance treatment strategies, challenges, and future research directions for FLT3-ITD mutant AML patients after transplantation.
